Menu Close

Trending

Measuring the cost-effectiveness of vaccines targeting infectious diseases
Could your loyalty card help spot cancer? Study says yes
JP Morgan 2023 – Adi Hoess
Tackling ongoing staffing burnout rates through AI-enabled precision oncology
Ipsen’s rare disease drug palovarotene knocked back in EU

mAbs

artificial intelligence antibody

Digital/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Artificial Intelligence for better antibody drugs: ready for prime time?

, , , , , , , , , 0 Comment

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be

X
Artificial Intelligence for better antibody drugs: ready for prime time?
https://pharmaphorum.com/views-and-analysis/artificial-intelligence-for-better-antibody-drugs-ready-for-prime-time/
How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

How cell and gene therapies are transforming pharma deal-making

, , , 0 Comment

After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to

X
How cell and gene therapies are transforming pharma deal-making
https://pharmaphorum.com/r-d/views-analysis-r-d/how-cell-and-gene-therapies-are-transforming-pharma-deal-making/

Login

CONTINUE TO SITE >
X
Close in 10 seconds